BioSpace News Archive

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration approved AMVUTTRA™, an RNAi therapeutic administered via subcutaneous injection once every three months for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Cogent Biosciences, Inc. announced the pricing of an underwritten public offering of 15,169,698 shares of its common stock, offered at a public offering price of $8.25 per share.

Homology Medicines, Inc., a genetic medicines company, announced that the U.S. Food and Drug Administration lifted the clinical hold previously placed on the pheNIX gene therapy clinical trial with investigational HMI-102 for adults with phenylketonuria.

Hillstream BioPharma, Inc. announced that its Board of Directors has authorized a share repurchase program to acquire up to $1 million of the Company’s common stock.

Daxor Corporation announces it will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18th, 2022 at the Rosen Shingle Creek Resort in Orlando, Florida.

AIM ImmunoTech Inc. announced that the Netherlands Patent Office has issued Patent No. 2027383 — a utility patent — covering Ampligen® and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.

Akero Therapeutics, Inc. announced that it will present oral and poster presentations at the Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies, being held in Keystone, Colorado, June 12-16.

Aeterna Zentaris Inc. announced its Autoimmunity Modifying Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder, a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis.

META Pharmaceuticals, China’s first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling 15 million USD.

Regulus Therapeutics Inc today announced the dosing of the first healthy volunteer in the Phase 1 SAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).